This study is designed to determine the long-term effects of 3 treatments (two classes of anti-inflammatory agents (udesonide or nedocromil) and placebo) over a 5-6-1/2 year period. Every patient will use an intermittent short acting B2-agonist (albuterol). Children, aged 5-12 (one third from ethnic minority groups), who have had asthma symptoms for nine or more months with chronic symptoms for at least 6 months during the past year (as indicated by symptoms more than once per week or at least twice weekly use of bronchodilators) will be studies.
Showing the most recent 10 out of 568 publications